| [1] |
YOUNOSSI Z, ANSTEE QM, MARIETTI M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20. DOI: 10.1038/nrgastro.2017.109. |
| [2] |
LUDWIG J, VIGGIANO TR, MCGILL DB, et al. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease[J]. Mayo Clin Proc, 1980, 55(7): 434-438.
|
| [3] |
ALKHOURI N, LAWITZ E, NOUREDDIN M, et al. GS-0976 (Firsocostat): An investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)[J]. Expert Opin Investig Drugs, 2020, 29(2): 135-141. DOI: 10.1080/13543784.2020.1668374. |
| [4] |
RATZIU V, SANYAL AJ, LOOMBA R, et al. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis[J]. Contemp Clin Trials, 2019, 84: 105803. DOI: 10.1016/j.cct.2019.06.017. |
| [5] |
DAVID D, EAPEN CE. What are the current pharmacological therapies for nonalcoholic fatty liver disease?[J]. J Clin Exp Hepatol, 2021, 11(2): 232-238. DOI: 10.1016/j.jceh.2020.09.001. |
| [6] |
ANANIA FA, DIMICK-SANTOS L, MEHTA R, et al. Nonalcoholic steatohepatitis: Current thinking from the division of hepatology and nutrition at the Food and Drug Administration[J]. Hepatology, 2021, 73(5): 2023-2027. DOI: 10.1002/hep.31687. |
| [7] |
GOULART E, de CAIRES-JUNIOR LC, TELLES-SILVA KA, et al. 3D bioprinting of liver spheroids derived from human induced pluripotent stem cells sustain liver function and viability in vitro[J]. Biofabrication, 2019, 12(1): 015010. DOI: 10.1088/1758-5090/ab4a30. |
| [8] |
RATZIU V, HARRISON SA, FRANCQUE S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and-δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J]. Gastroenterology, 2016, 150(5): 1147-1159. e5. DOI: 10.1053/j.gastro.2016.01.038. |
| [9] |
SHARMA M, PREMKUMAR M, KULKARNI AV, et al. Drugs for non-alcoholic steatohepatitis (NASH): Quest for the holy grail[J]. J Clin Transl Hepatol, 2021, 9(1): 40-50. DOI: 10.14218/JCTH.2020.00055. |
| [10] |
KIM W, KIM BG, LEE JS, et al. Randomised clinical trial: The efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2017, 45(8): 1073-1083. DOI: 10.1111/apt.13981. |
| [11] |
ALKHOURI N. Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: Rationale for the development of resmetirom (MGL-3196)[J]. Expert Opin Investig Drugs, 2020, 29(2): 99-101. DOI: 10.1080/13543784.2020.1708899. |
| [12] |
HARRISON SA, ROSSI SJ, PAREDES AH, et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis[J]. Hepatology, 2020, 71(4): 1198-1212. DOI: 10.1002/hep.30590. |
| [13] |
GENG L, LAM K, XU A. The therapeutic potential of FGF21 in metabolic diseases: From bench to clinic[J]. Nat Rev Endocrinol, 2020, 16(11): 654-667. DOI: 10.1038/s41574-020-0386-0. |
| [14] |
SANYAL A, CHARLES ED, NEUSCHWANDER-TETRI BA, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, phase 2a trial[J]. Lancet, 2019, 392(10165): 2705-2717. DOI: 10.1016/S0140-6736(18)31785-9. |
| [15] |
SAFADI R, KONIKOFF FM, MAHAMID M, et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2014, 12(12): 2085-2091. e1. DOI: 10.1016/j.cgh.2014.04.038. |
| [16] |
ARMSTRONG MJ, GAUNT P, AITHAL GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study[J]. Lancet, 2016, 387(10019): 679-690. DOI: 10.1016/S0140-6736(15)00803-X. |
| [17] |
NEWSOME PN, BUCHHOLTZ K, CUSI K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med, 2021, 384(12): 1113-1124. DOI: 10.1056/NEJMoa2028395. |
| [18] |
SHIMIZU M, SUZUKI K, KATO K, et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease[J]. Diabetes Obes Metab, 2019, 21(2): 285-292. DOI: 10.1111/dom.13520. |
| [19] |
JEONG SW. Nonalcoholic fatty liver disease: A drug revolution is coming[J]. Diabetes Metab J, 2020, 44(5): 640-657. DOI: 10.4093/dmj.2020.0115. |
| [20] |
INOUE M, HAYASHI A, TAGUCHI T, et al. Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease[J]. J Diabetes Investig, 2019, 10(4): 1004-1011. DOI: 10.1111/jdi.12980. |
| [21] |
KITAZAWA M, KATAGIRI T, SUZUKI H, et al. A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study[J]. Diabetes Obes Metab, 2021, 23(3): 811-821. DOI: 10.1111/dom.14288. |
| [22] |
ZHAO Q, LIU J, DENG H, et al. Targeting mitochondria-located circRNA SCAR alleviates NASH via reducing mros output[J]. Cell, 2020, 183(1): 76-93. e22. DOI: 10.1016/j.cell.2020.08.009. |
DownLoad: